New directions for drug discovery

Dialogues in Clinical Neuroscience

Volumn 8, Issue 3, 2006, Pages 295-301

  Spedding, Michael ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Drug discovery; Drug testing; Pathophysiology; Screening

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS; DIAZEPAM;

CARDIOVASCULAR DISEASE; DRUG ACTIVITY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; FINANCIAL MANAGEMENT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDICAL RESEARCH; MENTAL DISEASE; PATHOPHYSIOLOGY; REVIEW; SCREENING; STRUCTURE ACTIVITY RELATION;

ANIMALS; CLINICAL TRIALS; DRUG APPROVAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; MENTAL DISORDERS; PHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 33750588297     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Spedding M. Reasons why stroke trials underestimate the neuroprotective effects of drugs. Stroke. 2002;33, 324-325.
2. The PROGRESS Collaborative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:1069-1075.
3. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke. Circulation. 2005;112:1644-1650.
4. Collis MG. Integrative pharmacology and drug discovery - is the tide turning? Nature Drug Discovery. 2006:5, 377-379.
5. Foord SM, Bonner TI, Neubig RR, et al. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev. 2005;2:279-288.
6. Markham A, Cameron I, Franklin P, Spedding M. BDNF increases mitochondrial respiratory coupling, and glutamate metabolism, at complex I, but not complex II. Eur J Neurosci. 2004;20:1189-1196.
7. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nature Drug Discovery. 2005;4:919-927.
8. Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2c antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
9. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16:93-100.
10. Spedding M, Jay T, Costa e Silva J, Perret L. A pathophysiological paradigm for the therapy of psychiatric disease. Nature Drug Discovery. 2005;4:467-476.
11. Rocher C, Spedding M, Munoz C, Jay T. Acute stress-induced changes in cortical synaptic plasticity: interactions with antidepressants. Cereb Cortex. 2004;14, 224-229.
12. McEwen BS, Olié JP. Neurobiology of mood, anxiety and emotions, as revealed by studies of a unique antidepressant: tianeptine. Mol Psych. 2005;10:525-537.
13. Mayberg HS, Lozano A, Voon V, et al. Deep brain stimulation for treatment resistant depression. Neuron. 2005;45:651-660.